Therapeutic modulation of APP-CD74 axis can activate phagocytosis of TAMs in GBM
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2024-12 · 1870 (8) · 167449
DOI: 10.1016/j.bbadis.2024.167449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024-12. Verfasst von Chengcheng Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory o…. Hauptthemen laut MEDLINE: Glioblastoma, Phagocytosis, Antigens, Differentiation, B-Lymphocyte, Amyloid beta-Protein Precursor. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) remains the most lethal central nervous system cancer with poor survival and few targeted therapies. The GBM tumor microenvironment is complex and closely associated with outcomes. Here, we analyzed the cell-cell communication within the microenvironment and found the high level of cell communication between GBM tumor cells and tumor-associated macrophages (TAMs). We found that the amyloid protein precursor (APP)-CD74 axis displayed the highest levels of communication between GBM tumor cells and TAMs, and that APP and CD74 expression levels were significantly corelated with poorer patient outcomes. We showed that the expression of APP on the surface of GBM inhibited phagocytosis of TAMs through the binding of APP to the CD74/CXCR4 cell surface receptor complex. We further demonstrated that disrupting the APP-CD74 axis could upregulated the phagocytosis of TAMs in vitro and in vivo. Finally, we demonstrated that APP promotes the phosphorylation of SHP-1 by binding to CD74. Together, our findings revealed that the APP-CD74 axis was a highly expressed anti-phagocytic signaling pathway that may be a potential immunotherapeutic target for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery,…
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Ma, C., Chen, J., Ji, J., Zheng, Y., Liu, Y., Wang, J., Chen, T., Chen, H., Chen, Z., Zhou, Q., Hou, C., & Ke, Y. (2024). Therapeutic modulation of APP-CD74 axis can activate phagocytosis of TAMs in GBM. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1870(8), 167449. https://doi.org/10.1016/j.bbadis.2024.167449
Vancouver
Ma C, Chen J, Ji J, Zheng Y, Liu Y, Wang J, et al. Therapeutic modulation of APP-CD74 axis can activate phagocytosis of TAMs in GBM. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024;1870(8):167449. doi:10.1016/j.bbadis.2024.167449
BibTeX
@article{Ma2024,
author = {Ma, Chengcheng and Chen, Jiawen and Ji, Jingsen and Zheng, Yaofeng and Liu, Yang and Wang, Jihui and Chen, Taoliang and Chen, Huajian and Chen, Zetao and Zhou, Quanwei and Hou, Chongxian and Ke, Yiquan},
title = {Therapeutic modulation of APP-CD74 axis can activate phagocytosis of TAMs in GBM},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2024},
volume = {1870},
number = {8},
pages = {167449},
doi = {10.1016/j.bbadis.2024.167449}
}
EUVIMED